Roivant wins FDA approval for first oral dermatomyositis treatment
Roivant Sciences received FDA approval for brepocitinib, marketed as Lisraya, to treat dermatomyositis. This is the first oral therapy for the autoimmune condition and marks a significant regulatory win for the company. The approval could generate billions in revenue for Roivant.
Related stories
J&J's Imaavy becomes first approved therapy for rare anemia · Drug development
Fatal outcome surfaces in Chinese gene therapy study, raising transparency concerns · Drug development
Regeneron secures approval for ultra-rare bone disorder drug · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Roivant's dermatomyositis drug Lisraya snags FDA approval.” Browse more stories.